Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PDE9A | O76083 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 5/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 3/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.34 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 2/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16283736 | 0.81 | ATM (0.40) | ATMMEN1ALDH1A1THRBHPGD | |
| SCHEMBL8341630 | 0.74 | ATM (0.68) | ATM | |
| SCHEMBL16285449 | 0.73 | BTK (0.41) | MEN1ALDH1A1THRBHPGDKMT2A | |
| SCHEMBL14100560 | 0.72 | ATM (0.53) | ATM | |
| SCHEMBL8343433 | 0.71 | ATM (0.47) | ATMALDH1A1HPGD | |
| SCHEMBL13520606 | 0.68 | GRM2 (0.44) | MEN1ALDH1A1THRBHPGDKMT2A | |
| SCHEMBL15082480 | 0.66 | NISCH (0.55) | MEN1ALDH1A1KMT2A | |
| SCHEMBL21723344 | 0.66 | CRHR1 (0.36) | BACE1GRM2 | |
| SCHEMBL3265647 | 0.65 | ATM (0.65) | ATM | |
| SCHEMBL19998590 | 0.65 | COMT (0.42) | MEN1ALDH1A1KMT2APDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193736-B2 | PDE 10a inhibitors for the treatment of type II diabetes | JANSSEN PHARMACEUTICA, NV (BE) | 2015-11-24 | — | — | US | disclosed |
| US-20140364413-A1 | PDE 10a Inhibitors for the Treatment of Type II Diabetes | JANSSEN PHARMACEUTICA, NV (BE) | 2014-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364413-A1 | PDE 10a Inhibitors for the Treatment of Type II Diabetes | PDE2A, PDE3B, PDE3A | ATM 1139/4885MEN1 3624/4885ALDH1A1 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.